Open Access Open Access  Restricted Access Subscription Access

Exploring the Potent Power of Ionophore Antibiotics: A Brief Report on Lasalocid, Monensin and Salinomycin

Ambica Prasad M., Sony Sharlet E., Muralinath E., Mohan Naidu K., Srinivas Prasad, Jayinder Paul Singh. G., Panjan Ghosh. P., Kalyan C., Archana Jain, Guruprasad M., Ramanjaneyulu D. V.

Abstract


Ionosphere has attracted attention in a significant  manner in both veterinary  and human medicine because of their remarkable  biological activities.   Lasalocid exhibits potent activity against Gram_ positive bacteria,  especially   in ruminants namely  cattle, sheep and goats. Monensin is widely used in animal feed, especially  in Poultry and cattle. To enhance growth and inhibit diseases caused by Gram_ positive  bacteria and  coccidia.  Salinomycin shows its potent activity especially  against  Gram_ positive bacteria,  including multidrug_ resistant  strains such as methicillin_ resistant Staphylococcud aureus  ( MRSA ).  Finally  it is concluded  that Ionophore antibiotics, including lasalocid, monensin and salinimycin represent a diverse and potent arsenal of compounds with applications ranging from veterinary  medicine to cancer therapy.


Full Text:

PDF

References


Mitani M, Yamanishi T, Miyazaki Y. Salinomycin: A new monovalent cation ionophore. Biochem Biophys Res Commun. 1975;66:1231–1236. [PubMed] [Google Scholar]

Gupta PB, Onder TT, Jiang G, et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009;138:645–659. [PMC free article] [PubMed] [Google Scholar]

Dong TT, Zhou HM, Wang LL, et al. Salinomycin selectively targets 'CD133+' cell subpopulations and decreases malignant traits in colorectal cancer lines. Ann Surg Oncol. 2011;18:1797–1804. [PubMed] [Google Scholar]

Kim KY, Yu SN, Lee SY, et al. Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 2011;413:80–86. [PubMed] [Google Scholar]

Kusunoki S, Kato K, Tabu K, et al. The inhibitory effect of salinomycin on the proliferation, migration and invasion of human endometrial cancer stem-like cells. Gynecol Oncol. 2013;129:598–605. [PubMed] [Google Scholar]

Lu D, Choi MY, Yu J, et al. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 2011;108:13253–13257. [PMC free article] [PubMed] [Google Scholar]

Chen T, Yi L, Li F, et al. Salinomycin inhibits the tumor growth of glioma stem cells by selectively suppressing glioma-initiating cells. Mol Med Rep. 2015;11:2407–2412. [PMC free article] [PubMed] [Google Scholar]

Tang QL, Zhao ZQ, Li JC, et al. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. Cancer Lett. 2011;311:113–121. [PubMed] [Google Scholar]

Fuchs D, Heinold A, Opelz G, et al. Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 2009;390:743–749. [PubMed] [Google Scholar]

Kopp F, Hermawan A, Oak PS, et al. Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer. 2014;13:16. [PMC free article] [PubMed] [Google Scholar]

Schenk M, Aykut B, Teske C, et al. Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. Cancer Lett. 2015;358:161–169. [PubMed] [Google Scholar]

Ketola K, Hilvo M, Hyötyläinen T, et al. Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 2012;106:99–106. [PMC free article] [PubMed] [Google Scholar]

Li T, Su L, Zhong N, et al. Salinomycin induces cell death with autophagy through activation of endoplasmic reticulum stress in human cancer cells. Autophagy. 2013;9:1057–1068. [PMC free article] [PubMed] [Google Scholar]

Sánchez-Tilló E, Fanlo L, Siles L, et al. The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma. Cell Death Differ. 2014;21:247–257. [PMC free article] [PubMed] [Google Scholar]

Kim JH, Chae M, Kim WK, et al. Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 2011;162:773–784. [PMC free article] [PubMed] [Google Scholar]

Kim JH, Yoo HI, Kang HS, et al. Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochem Biophys Res Commun. 2012;418:98–103. [PubMed] [Google Scholar]

Najumudeen AK, Jaiswal A, Lectez B, et al. Cancer stem cell drugs target K-ras signaling in a stemness context. Oncogene. 2016 Epub ahead of print. [PMC free article] [PubMed] [Google Scholar]

Boesch M, Zeimet AG, Rumpold H, et al. Drug transporter-mediated protection of cancer stem cells from ionophore antibiotics. Stem Cells Translational Medicine. 2015;4:1028–1032. [PMC free article] [PubMed] [Google Scholar]

Naujokat C, Steinhart R. Salinomycin as a drug for targeting human cancer stem cells. J Biomed Biotechnol. 2012;2012:950658. [PMC free article] [PubMed] [Google Scholar]

Boehmerle W, Endres M. Salinomycin induces calpain and cytochrome c-mediated neuronal cell death. Cell Death Dis. 2011;2:e168. [PMC free article] [PubMed] [Google Scholar]

Scherzad A, Hackenberg S, Schramm C, et al. Geno- and cytotoxicity of salinomycin in human nasal mucosa and peripheral blood lymphocytes. Toxicol In Vitro. 2015;29:813–818. [PubMed] [Google Scholar]

Boehmerle W, Muenzfeld H, Springer A, et al. Specific targeting of neurotoxic side effects and pharmacological profile of the novel cancer stem cell drug salinomycin in mice. J Mol Med (Berl) 2014;92:889–900. [PubMed] [Google Scholar]

Pattabiraman DR, Weinberg RA. Tackling the cancer stem cells—what challenges do they pose? Nat Rev Drug Discov. 2014;13:497–512. [PMC free article] [PubMed] [Google Scholar]

Lu Y, Ma W, Mao J, et al. Salinomycin exerts anticancer effects on human breast carcinoma MCF-7 cancer stem cells via modulation of hedgehog signaling. Chem Biol Interact. 2015;228:100–107. [PubMed] [Google Scholar]

Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275–284. [PubMed] [Google Scholar]

Boesch M, Zeimet AG, Fiegl H, et al. High prevalence of side population in human cancer cell lines. Oncoscience. 2016;3:85–87. [PMC free article] [PubMed] [Google Scholar]

Boesch M, Zeimet AG, Reimer D, et al. The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristics. Oncotarget. 2014;5:7027–7039. [PMC free article] [PubMed] [Google Scholar]

Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 2008;451:345–349. [PMC free article] [PubMed] [Google Scholar]


Refbacks

  • There are currently no refbacks.